DOCSLIB.ORG

Enhanced Unique Pattern of Hematopoietic Cell Mobilization Induced by the CXCR4 Antagonist 4F-Benzoyl-TN14003

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Enhanced Unique Pattern of Hematopoietic Cell Mobilization Induced by the CXCR4 Antagonist 4F-Benzoyl-TN14003 CANCER STEM CELLS Enhanced Unique Pattern of Hematopoietic Cell Mobilization Induced by the CXCR4 Antagonist 4F-Benzoyl-TN14003 MICHAL ABRAHAM,a KATIA BIYDER,a MICHAL BEGIN,a HANNA WALD,a IDO D. WEISS,a EITHAN GALUN,a Downloaded from ARNON NAGLER,b AMNON PELEDa aGoldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel; bBone Marrow Transplantation Department, Chaim Sheba Medical Center, Tel-Hashomer, Israel Key Words. CXCR4 • Mobilization • Hematopoietic stem cells • Hematopoietic progenitors www.StemCells.com ABSTRACT An increase in the number of stem cells in blood following cells (WBC) in blood, including monocytes, B cells, and T mobilization is required to enhance engraftment after high- cells, it had no effect on mobilizing natural killer cells. dose chemotherapy and improve transplantation outcome. T-140 was found to efficiently synergize with granulocyte Therefore, an approach that improves stem cell mobilization colony-stimulating factor (G-CSF) in its ability to mobi- is essential. The interaction between CXCL12 and its recep- lize WBC and progenitors, as well as to induce a 660-fold tor, CXCR4, is involved in the retention of stem cells in the increase in the number of erythroblasts in peripheral at Bernman National Medical Library, Hebrew University of Jerusalem on April 18, 2009 bone marrow. Therefore, blocking CXCR4 may result in blood. Comparison between the CXCR4 antagonists mobilization of hematopoietic progenitor and stem cells. We T-140 and AMD3100 showed that T-140 with or without have found that the CXCR4 antagonist known as 4F-benzo- G-CSF was significantly more potent in its ability to yl-TN14003 (T-140) can induce mobilization of hematopoi- mobilize hematopoietic stem cells and progenitors into etic stem cells and progenitors within a few hours post- blood. These results demonstrate that different CXCR4 treatment in a dose-dependent manner. Furthermore, antagonists may have different therapeutic potentials. although T-140 can also increase the number of white blood STEM CELLS 2007;25:2158–2166 Disclosure of potential conflicts of interest is found at the end of this article. Granulocyte colony-stimulating factor (G-CSF)-mobilized INTRODUCTION peripheral-blood mononuclear cells are routinely used as a source of HSCs for transplantation. Despite the potency of All mature blood cells are derived from hematopoietic stem G-CSF in mobilizing stem cells, it results in broad interindi- cells (HSCs) through intermediates that are termed hematopoi- vidual variations in circulating progenitor and stem cell numbers etic progenitor cells (HPCs) [1]. Hematopoietic cells at various [4], requiring repeated dosing, and is frequently associated with stages of differentiation are localized within the bone marrow side effects. Thus, optimal and improved methods to mobilize (BM), their main site of production. Their trafficking between and collect peripheral-blood progenitor and stem cells for he- BM and blood is a physiological process [2, 3], but under matopoietic rescue are warranted. steady-state conditions, HPCs and HSCs circulate in peripheral Over recent years, it has become apparent that the interac- blood at very low frequency. Stem cell frequencies in peripheral tion between CXCL12 and its receptor, CXCR4, plays a pivotal blood can be considerably increased both in response to various role in hematopoietic cell mobilization and engraftment [5–7]. growth factors and during the recovery phase following myelo- The CXCR4 receptor is widely expressed on many cell types, suppressive chemotherapy, a process termed mobilization. Cir- including HSCs and HPCs, and the interaction with its ligand culating stem cells are capable of homing to the BM and was found to be involved in chemotaxis, homing, and survival. regenerating normal hematopoiesis following myeloablative The CXCL12/CXCR4 axis is also involved in the retention of conditioning with high doses of chemotherapy or radiation. hematopoietic cells within the BM microenvironment [8]; con- Recently, the use of peripheral blood as a source of stem cells sequently, the disruption of CXCL12/CXCR4 interactions re- for patients undergoing autologous and allogeneic transplanta- sults in mobilization of hematopoietic cells. Indeed, blocking tion has replaced BM as the preferred source of hematopoietic the CXCR4 receptor with an antagonist, such as AMD3100, rescue. Under steady-state conditions, HPCs and HSCs circulate results in the mobilization of HPCs. Moreover, combining in blood at frequencies too low to allow for efficient collection AMD3100 with G-CSF has produced an additive effect [9]. of numbers sufficient for transplantation. Therefore, an increase These approaches suggest that antagonizing the interactions of in the number of HSCs in blood following mobilization im- BM-produced CXCL12 with CXCR4 that is expressed on HSCs proves transplantation efficiency by shortening the duration of could be an effective HSC mobilizing strategy. cytopenia, enhances immune reconstitution, and reduces mor- Today, there are several known CXCR4 antagonists that bidity. have been described as having different levels of efficiency [10, Correspondence: Amnon Peled, Ph.D., Hadassah Hebrew University Hospital, Gene Therapy Institute, P.O. Box 12000, Jerusalem, 91120 Israel. Telephone: 972-2-677-8780; Fax: 972-2-643-0982; e-mail: [email protected] Received March 6, 2007; accepted for publication May 15, 2007; first published online in STEM CELLS EXPRESS May 24, 2007. ©AlphaMed Press 1066-5099/2007/$30.00/0 doi: 10.1634/stemcells.2007-0161 STEM CELLS 2007;25:2158–2166 www.StemCells.com Abraham, Biyder, Begin et al. 2159 11]. 4F-benzoyl-TN14003 (T-140) is a short modified peptide Migration Assay (supplemental online Fig. 1), a highly selective CXCR4 antag- A migration assay with human Jurkat T cells was assayed by using onist, originally designed as a human immunodeficiency virus Costar migration buffer (6.5 mm/diameter, 5 ␮m/pore; Corning (HIV) entry inhibitor through specific binding to CXCR4. T-140 Costar, Cambridge, MA, http://www.corning.com/lifesciences; is a competitive inhibitor that hinders CXCL12-mediated cell RPMI 1640, 1% FCS) containing 2 ϫ 105 Jurkat cells added to the proliferation and migration [12]. upper chamber, and 0.6 ml of chemotaxis buffer with or without To determine the therapeutic potential of T-140, we evalu- CXCL12 (50 ng/ml) and with or without T-140 or T-140 pretreated ated the capacity of T-140 to mobilize hematopoietic cells, alone with proteinase K was added to the bottom chamber. Cells migrat- Downloaded from and in combination with G-CSF. In addition, we compared the ing within 4 hours to the bottom chamber of the Transwell were effect of T-140 to that of another CXCR4 antagonist, counted using FACSCalibur (BD Biosciences, San Jose, CA, http:// AMD3100. www.bdbioscience.com). HPC Assay MATERIALS AND METHODS To evaluate the number of progenitor cells, a colony-forming cell assay was used. Burst-forming units-erythrocyte (BFU-E), colony- forming units granulocyte-macrophage (CFU-GM), colony-forming www.StemCells.com Reagents units megakaryocytes (CFU-M), and colony-forming units granu- AMD3100 was purchased from Sigma-Aldrich (Rehovot, Israel, locyte-erythroblasts-macrophages-megakaryocyte (CFU-GEMM) http://www.sigmaaldrich.com). G-CSF (Neupogen [filgrastim], were assayed by plating the cells in Iscove’s modified Dulbecco’s Amgen, Thousand Oaks, CA, http://www.amgen.com) was kindly medium containing 1% methylcellulose, 15% fetal bovine serum, provided by Prof. Arnon Nagler. T-140 was kindly provided by 1% bovine serum albumin, 3 U/ml recombinant human (rh) EPO, Biokine Therapeutics, Ltd. The activity of T-140 was neutralized by 104 M 2-mercaptoethanol, 2 mM L-glutamine, 50 ng/ml recombi- incubating with Proteinase K (DAKO, Glostrup, Denmark, http:// nant mouse (rm)SCF, 10 ng/ml rmIL-3, 10 ␮g/ml rh insulin, 10 www.dako.com) for 20 minutes at 37°C followed by 10 minutes of ng/ml rh interleukin-6 (IL-6), and 200 ␮g/ml human transferrin at Bernman National Medical Library, Hebrew University of Jerusalem on April 18, 2009 incubation at 95°C. (Methocult GF M3434; Stem Cell Technologies, Vancouver, BC, Canada, http://www.stemcell.com). The cultures were incubated at Mice and Experimental Protocol 37°C in a humidified atmosphere containing 5% CO2. Seven days later, typical colonies were visually scored by morphologic criteria Female C57BL/6 mice (7–8 weeks old) were purchased from Har- using a light microscope, and the frequency of CFU was calculated. lan Israel (Rehovot, Israel, http://www.harlanisrael.com) and main- Staining colonies with benzidine dihydrochloride (Sigma-Aldrich) tained under specific pathogen-free conditions at the Hebrew Uni- was used to localize hemoglobin-containing cells. versity Animal Facility (Jerusalem, Israel). All experiments were approved by the Animal Care and Use Committee of the Hebrew University (Jerusalem, Israel). Mice were injected subcutaneously HSC Assay with various doses of T-140 or AMD3100 (1, 2.5, 5, and 10 mg/kg) C57BL/6 mice, serving as donors, were injected with 5 mg/kg of in a total volume of 200 ␮l, 2 hours before sacrifice. In some either T-140 or AMD3100. Two hours later, peripheral blood cells experiments, mice were sacrificed at different time points: 1⁄2,1,2, were collected, followed by erythrocyte lysis (as described above), 4, and 24 hours postinjection. G-CSF was subcutaneously injected and i.v. transferred into C57BL/6 recipient mice that had been at a dose of 2.5 ␮g per mouse twice a day for 4 days. In the pretreated with a lethal dose of irradiation (900 cGy) 24 hours combination experiments, 18 hours after the last injection of G- before. Total cells obtained from 900 or 225 ␮l of blood were CSF, mice were injected with either T-140 or AMD3100. Control inoculated into a single recipient mouse in a total volume of 200 ␮l mice were injected with phosphate-buffered saline (PBS) at the of PBS. Recipient mice that were inoculated with cells obtained appropriate volume.
Load more

Recommended publications
  • Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid
    Published OnlineFirst August 23, 2017; DOI: 10.1158/1078-0432.CCR-16-2919 Cancer Therapy: Clinical Clinical Cancer Research Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34þ Cells in Healthy Volunteers Michal Abraham1, Yaron Pereg2, Baruch Bulvik1, Shiri Klein3, Inbal Mishalian3, Hana Wald1, Orly Eizenberg1, Katia Beider4, Arnon Nagler4, Rottem Golan2, Abi Vainstein2, Arnon Aharon2, Eithan Galun3, Yoseph Caraco5, Reuven Or6, and Amnon Peled3,4 Abstract Purpose: The potential of the high-affinity CXCR4 antagonist systemic reactions were mitigated by methylprednisolone, BL-8040 as a monotherapy-mobilizing agent and its derived paracetamol, and promethazine pretreatment. In the first part graft composition and quality were evaluated in a phase I clinical of the study, BL-8040 triggered rapid and substantial mobili- þ study in healthy volunteers (NCT02073019). zation of WBCs and CD34 cells in all tested doses. Four hours Experimental Design: The first part of the study was a ran- postdose, the count rose to a mean of 8, 37, 31, and 35 cells/mL domized, double-blind, placebo-controlled dose escalation (placebo, 0.5, 0.75, and 1 mg/kg, respectively). FACS analysis phase. The second part of the study was an open-label phase, in revealed substantial mobilization of immature dendritic, T, B, þ which 8 subjects received a single injection of BL-8040 (1 mg/kg) and NK cells. In the second part, the mean CD34 cells/kg and approximately 4 hours later underwent a standard leukapher- collected were 11.6 Â 106 cells/kg. The graft composition was esis procedure.
    [Show full text]
  • Modulators of CXCR4 and CXCR7/ACKR3 Function
    Molecular Pharmacology Fast Forward. Published on September 23, 2019 as DOI: 10.1124/mol.119.117663 This article has not been copyedited and formatted. The final version may differ from this version. MOL # 117663 Modulators of CXCR4 and CXCR7/ACKR3 function Ilze Adlere*, Birgit Caspar*, Marta Arimont*, Sebastian Dekkers, Kirsten Visser, Jeffrey Stuijt, Chris de Graaf, Michael Stocks, Barrie Kellam, Stephen Briddon, Maikel Wijtmans, Iwan de Esch, Stephen Hill, Rob Leurs# * These authors contributed equally to this work. Downloaded from # Corresponding author molpharm.aspetjournals.org Griffin Discoveries BV, Amsterdam, The Netherlands (IA, IE, RL), Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, UK (BC, SJB, SJH), Centre of Membrane Proteins and Receptors (COMPARE), Universities of Birmingham and Nottingham, The Midlands, U.K. (BC, BK, SD, SB, SH), at ASPET Journals on September 26, 2021 School of Pharmacy, University of Nottingham, Nottingham, U.K. (SD, BK, MS), Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (MA, KS, JS, CG, MW, IE, RL), Sosei Heptares, Cambridge, U.K. (CG) 1 Molecular Pharmacology Fast Forward. Published on September 23, 2019 as DOI: 10.1124/mol.119.117663 This article has not been copyedited and formatted. The final version may differ from this version. MOL # 117663 Running title: Modulators of CXCR4 and CXCR7/ACKR3 function Corresponding
    [Show full text]
  • Dynamic Chemotherapy-Induced Upregulation of CXCR4 Expression: a Mechanism of Therapeutic Resistance in Pediatric AML
    Published OnlineFirst June 10, 2013; DOI: 10.1158/1541-7786.MCR-13-0114 Molecular Cancer Cell Death and Survival Research Dynamic Chemotherapy-Induced Upregulation of CXCR4 Expression: A Mechanism of Therapeutic Resistance in Pediatric AML Edward Allan R. Sison, Emily McIntyre, Daniel Magoon, and Patrick Brown Abstract Cure rates in pediatric acute leukemias remain suboptimal. Overexpression of the cell-surface chemokine receptor CXCR4 is associated with poor outcome in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Certain nonchemotherapeutic agents have been shown to modulate CXCR4 expression and alter leukemia interactions with stromal cells in the bone marrow microenvironment. Because chemotherapy is the mainstay of AML treatment, it was hypothesized that standard cytotoxic chemotherapeutic agents induce dynamic changes in leukemia surface CXCR4 expression, and that chemotherapy-induced upregulation of CXCR4 repre- sents a mechanism of acquired therapeutic resistance. Here, it was shown that cell lines variably upregulate CXCR4 with chemotherapy treatment. Those that showed upregulation were differentially protected from chemotherapy- induced apoptosis when cocultured with stroma. The functional effects of chemotherapy-induced CXCR4 up- regulation in an AML cell line (MOLM-14, which harbors consistent upregulated CXCR4) and clinical specimens were explored. Importantly, enhanced stromal-cell derived factor-1a (SDF1A/CXCL12)-mediated chemotaxis and stromal protection from additional chemotherapy-induced apoptosis was found. Furthermore, treatment with plerixafor, a CXCR4 inhibitor, preferentially decreased stromal protection with higher chemotherapy-induced upregulation of surface CXCR4. Thus, increased chemokine receptor CXCR4 expression after treatment with conventional chemotherapy may represent a mechanism of therapeutic resistance in pediatric AML. Implications: CXCR4 may be a biomarker for the stratification and optimal treatment of patients using CXCR4 inhibitors.
    [Show full text]
  • Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
    REVIEW published: 09 July 2021 doi: 10.3389/fimmu.2021.686155 Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis † † Jie Huang 1 , Xuekun Fu 1 , Xinxin Chen 1, Zheng Li 1, Yuhong Huang 1 and Chao Liang 1,2* 1 Department of Biology, Southern University of Science and Technology, Shenzhen, China, 2 Institute of Integrated Bioinfomedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China Rheumatoid arthritis (RA) is a systemic poly-articular chronic autoimmune joint disease that mainly damages the hands and feet, which affects 0.5% to 1.0% of the population worldwide. With the sustained development of disease-modifying antirheumatic drugs (DMARDs), significant success has been achieved for preventing and relieving disease activity in RA patients. Unfortunately, some patients still show limited response to DMARDs, which puts forward new requirements for special targets and novel therapies. Understanding the pathogenetic roles of the various molecules in RA could facilitate discovery of potential therapeutic targets and approaches. In this review, both Edited by: existing and emerging targets, including the proteins, small molecular metabolites, and Trine N. Jorgensen, epigenetic regulators related to RA, are discussed, with a focus on the mechanisms that Case Western Reserve University, result in inflammation and the development of new drugs for blocking the various United States modulators in RA. Reviewed by: Åsa Andersson, Keywords: rheumatoid arthritis, targets, proteins, small molecular metabolites, epigenetic regulators Halmstad University, Sweden Abdurrahman Tufan, Gazi University, Turkey *Correspondence: INTRODUCTION Chao Liang [email protected] Rheumatoid arthritis (RA) is classified as a systemic poly-articular chronic autoimmune joint † disease that primarily affects hands and feet.
    [Show full text]
  • Extrinsic Targeting Strategies Against Acute Myeloid Leukemic Stem Cells Noureldien H
    Integrative Cancer Science and Therapeutics Review Article ISSN: 2056-4546 Extrinsic targeting strategies against acute myeloid leukemic stem cells Noureldien H. E. Darwish1,2 and Shaker A. Mousa2* 1Department of Clinical Pathology, Hematology Unit, Mansoura University, Egypt 2The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences (ACPHS), USA Abstract Despite advances in the treatment of acute myeloid leukemia (AML), patients still show high relapse and resistance against conventional chemotherapy. This resistance is related to a small clone referred to as Leukemia Stem Cells (LSCs). New targeted strategies are directed against the LSCs’ extrinsic regulators including their microenvironment such as a CXCR4 antagonist that is used to interfere with LSCs’ homing. Targeting LSCs’ surface molecules such as CD33 for selective elimination of LSCs has variable degrees of success that may require further assessments. Trials with CARs cells were effective in eradication of acute lymphoblastic leukemia, and they may have an effective role also in AML. Other strategies are directed against the intrinsic regulators such as self-renewal mechanisms and epigenetic reprogramming of LSCs. This review highlights targeting of the extrinsic regulators of the LSCs and identifies biological differences between them and normal hematopoietic stem cells. Introduction LSCs theory and properties Acute myeloid leukemia (AML) is a hematological disorder LSCs are able to divide to progeny clonogenic blast cells, leading to characterized by a malignant clone thought to be derived from a small the concept that AML is arranged in a hierarchy, with the LSCs present number of cells known as leukemic stem cells (LSCs). LSCs have a at the apex and the more “differentiated” blasts representing the main great ability for limitless self-renewal and also generation of leukemic tumor bulk [7].
    [Show full text]
  • Protocol Alert
    PROTOCOL ALERT New Clinical Trials Recently Added to the National Cancer Institute’s Database BLADDER CANCER Phase 1/1b Study to Evaluate the Safety Trial IDs: 556-15, NCI-2015-01502, and Tolerability of CPI-444 Alone and NCT02553447 Type: Biomarker/Laboratory analysis, A Study Of Avelumab In Patients in Combination With Atezolizumab in Treatment With Locally Advanced Or Metastatic Advanced Cancers Ibrutinib in Treating Minimal Residual Age: 18 to 75 Urothelial Cancer (JAVELIN Bladder Status: Active Disease in Patients With Chronic Trial IDs: UW14113, NCI-2015-02269, 100) Phase: Phase I Lymphocytic Leukemia After Front- 2015-0996, NCT02652468 Status: Active Type: Treatment Line Therapy Phase: Phase III Age: 18 and over Status: Active ESOPHAGEAL CANCER Type: Treatment Trial IDs: CPI-444-001, NCI-2016- Phase: Phase II Age: 18 and over 00227, NCT02655822 Type: Biomarker/Laboratory analysis, Proton Beam Radiation Therapy Trial IDs: B9991001, NCI-2016-00304, Treatment or Intensity-Modulated Radiation 2015-003262-86, JAVELIN Bladder 100, Circulating Tumor Cells in Operative Age: 18 and over Therapy in Treating Patients With NCT02603432 Blood in Patients With Bladder Cancer Trial IDs: MC1481, NCI-2015-02153, Esophageal Cancer Status: Not yet active NCT02649387 Status: Active A Study of Intravesical Apaziquone Phase: No phase specified Phase: Phase III as a Surgical Adjuvant in Patient Type: Biomarker/Laboratory analysis, Ibrutinib or Idelalisib in Treating Type: Treatment Undergoing TURBT Natural history/Epidemiology Patients With Persistent
    [Show full text]
  • Updates on the Hematologic Tumor Microenvironment and Its
    REVIEW ARTICLE Updates on the hematologic tumor Ferrata Storti Foundation microenvironment and its therapeutic targeting Dorian Forte, 1,2 Daniela S. Krause, 3 Michael Andreeff, 4 Dominique Bonnet 5 and Simón Méndez-Ferrer 1-2 Haematologica 2019 1 Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute and Department Volume 104(10):1928-1934 of Haematology, University of Cambridge, Cambridge, UK; 2National Health Service Blood and Transplant, Cambridge Biomedical Campus, Cambridge, UK; 3Goethe University Frankfurt, Georg-Speyer-Haus, Frankfurt, Germany; 4Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA and 5Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, UK ABSTRACT n this review article, we present recent updates on the hematologic tumor microenvironment following the 3 rd Scientific Workshop on the IHaematological Tumour Microenvironment and its Therapeutic Targeting organized by the European School of Hematology, which took place at the Francis Crick Institute in London in February 2019. This review article is focused on recent scientific advances highlighted in the invited pre - sentations at the meeting, which encompassed the normal and malignant niches supporting hematopoietic stem cells and their progeny. Given the precise focus, it does not discuss other relevant contributions in this field, which have been the scope of other recent reviews. The content covers basic research and possible clinical applications
    [Show full text]
  • WO 2017/223229 Al 28 December 2017 (28.12.2017) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2017/223229 Al 28 December 2017 (28.12.2017) W !P O PCT (51) International Patent Classification: (74) Agent: RED), Andrea L.C. et al; One International A61K 31/445 (2006.01) C07D 221/00 (2006.01) Place, 40th Floor, 100 Oliver Street, Boston, Massachusetts A61K 31/451 (2006.01) C07D 227/04 (2006.01) 021 10-2605 (US). A61K 31/4523 (2006.01) C07D 235/06 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US2017/038590 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (22) International Filing Date: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 2 1 June 2017 (21 .06.2017) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (25) Filing Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (26) Publication Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (30) Priority Data: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TH, TJ, TM, TN, 62/352,816 2 1 June 2016 (21 .06.2016) US TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced
    Author Manuscript Published OnlineFirst on April 11, 2014; DOI: 10.1158/1078-0432.CCR-13-2686 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer Matthew D. Galsky1*, Nicholas J. Vogelzang1, Paul Conkling2, Eyas Raddad3, John Polzer3, Stephanie Roberson3, John R. Stille3, Mansoor Saleh4, Donald Thornton5 1US Oncology Research/Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA 2 US Oncology Research/Virginia Oncology Associates, Norfolk, Virginia, USA 3The Chorus Group, Eli Lilly and Company, Indianapolis, IN, USA 4Georgia Cancer Specialists, PC, Atlanta, Georgia, USA 5Eli Lilly and Company, Indianapolis, IN, USA *Corresponding Author: Matthew D. Galsky, MD Mount Sinai School of Medicine 10 East 102nd Street Tower Building, Second Floor Box 1128 New York, NY 10029 Phone: 212-824-8583 Fax: 646-537-9639 [email protected] Running header: LY2510924 in patients with advanced cancer Keywords: CXCR4, LY2510924, cancer, CD34+ Word Count Abstract- 245 (Clinical Cancer Research limit = 250) Word Count Text- 4030 (CCR limit = 5000) Tables/Figures-6 (CCR limit = 6) Research support: The study was sponsored by Eli Lilly and Company. 1 Downloaded from clincancerres.aacrjournals.org on October 2, 2021. © 2014 American Association for Cancer Research. Author Manuscript Published OnlineFirst on April 11, 2014; DOI: 10.1158/1078-0432.CCR-13-2686 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Statement of clinical relevance (required for submission to journal): This manuscript reports the results of a phase I study designed to evaluate the safety and tolerability of the C-X-C motif receptor 4 (CXCR4) inhibitor LY2510924 in patients with advanced cancer.
    [Show full text]
  • Interplay Between SARS-Cov-2 and the Type I Interferon Response Margarida Sa Ribero, Nolwenn Jouvenet, Marlène Dreux, Sébastien Nisole
    Interplay between SARS-CoV-2 and the type I interferon response Margarida Sa Ribero, Nolwenn Jouvenet, Marlène Dreux, Sébastien Nisole To cite this version: Margarida Sa Ribero, Nolwenn Jouvenet, Marlène Dreux, Sébastien Nisole. Interplay between SARS- CoV-2 and the type I interferon response. PLoS Pathogens, Public Library of Science, 2020, 16 (7), pp.e1008737. 10.1371/journal.ppat.1008737. inserm-02965704 HAL Id: inserm-02965704 https://www.hal.inserm.fr/inserm-02965704 Submitted on 13 Oct 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License PLOS PATHOGENS REVIEW Interplay between SARS-CoV-2 and the type I interferon response 1 2 1 3 Margarida Sa RiberoID , Nolwenn Jouvenet *, Marlène DreuxID *, SeÂbastien NisoleID * 1 CIRI, Inserm, U1111, Universite Claude Bernard Lyon 1, CNRS, E cole Normale SupeÂrieure de Lyon, Univ Lyon, Lyon, France, 2 Institut Pasteur, CNRS UMR3569, Paris, France, 3 IRIM, CNRS UMR9004, Universite de Montpellier, Montpellier, France * [email protected] (NJ); [email protected] (MD); [email protected] (SN) a1111111111 a1111111111 a1111111111 Abstract a1111111111 a1111111111 The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the current COVID-19 pandemic.
    [Show full text]
  • A Highly Selective and Potent CXCR4 Antagonist for Hepatocellular Carcinoma Treatment
    A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment Jen-Shin Songa,1, Chih-Chun Changb,1, Chien-Huang Wua,1, Trinh Kieu Dinhb, Jiing-Jyh Jana, Kuan-Wei Huangb, Ming-Chen Choua, Ting-Yun Shiueb, Kai-Chia Yeha, Yi-Yu Kea, Teng-Kuang Yeha, Yen-Nhi Ngoc Tab, Chia-Jui Leea, Jing-Kai Huanga, Yun-Chieh Sungb, Kak-Shan Shiaa,2, and Yunching Chenb,2 aInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, Republic of China; and bInstitute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, 30013 Hsinchu, Taiwan, Republic of China Edited by Michael Karin, University of California San Diego, La Jolla, CA, and approved February 4, 2021 (received for review July 23, 2020) The CXC chemokine receptor type 4 (CXCR4) receptor and its ligand, advanced HCC (9, 17), the concept of which has been experimentally CXCL12, are overexpressed in various cancers and mediate tumor validated by the discovery of a CXCR4 antagonist, BPRCX807. progression and hypoxia-mediated resistance to cancer therapy. AMD3100 was the first Food and Drug Administration (FDA)- While CXCR4 antagonists have potential anticancer effects when approved CXCR4 antagonist used for peripheral blood stem cell combined with conventional anticancer drugs, their poor potency transplantation (PBSCT) (18); however, its application to solid against CXCL12/CXCR4 downstream signaling pathways and sys- tumors is limited by its poor pharmacokinetics and toxic adverse temic toxicity had precluded clinical application. Herein, BPRCX807, effects after long-term administration (19, 20). Thus, a CXCR4 known as a safe, selective, and potent CXCR4 antagonist, has been antagonist with higher safety and better pharmacological and designed and experimentally realized.
    [Show full text]
  • Current Insights Into Immunology and Novel Therapeutics of Atopic Dermatitis
    cells Review Current Insights into Immunology and Novel Therapeutics of Atopic Dermatitis Hidaya A. Kader 1,†, Muhammad Azeem 2,†, Suhib A. Jwayed 1, Aaesha Al-Shehhi 1 , Attia Tabassum 3, Mohammed Akli Ayoub 1 , Helal F. Hetta 4 , Yasir Waheed 5 , Rabah Iratni 1 , Ahmed Al-Dhaheri 6 and Khalid Muhammad 1,* 1 Department of Biology, College of Science, UAE University, Al Ain 15551, United Arab Emirates; [email protected] (H.A.K.); [email protected] (S.A.J.); [email protected] (A.A.-S.); [email protected] (M.A.A.); [email protected] (R.I.) 2 Department of Pathology, University of Würzburg, 97080 Würzburg, Germany; [email protected] 3 Department of Dermatology, Mayo Hospital, Lahore 54000, Pakistan; [email protected] 4 Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt; [email protected] 5 Foundation University Medical College, Foundation University Islamabad, Islamabad 44000, Pakistan; [email protected] 6 Department of Dermatology, Tawam Hospital, Al Ain 15551, United Arab Emirates; [email protected] * Correspondence: [email protected] † Authors contributed equally to this work. Abstract: Atopic dermatitis (AD) is one of the most prevalent inflammatory disease among non-fatal skin diseases, affecting up to one fifth of the population in developed countries. AD is characterized by recurrent pruritic and localized eczema with seasonal fluctuations. AD initializes the phenomenon Citation: Kader, H.A.; Azeem, M.; of atopic march, during which infant AD patients are predisposed to progressive secondary allergies Jwayed, S.A.; Al-Shehhi, A.; such as allergic rhinitis, asthma, and food allergies.
    [Show full text]